Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort

Karin Malickova, Peter L. Lakatos, Martin Bortlik, Viktor Komarek, Ivana Janatkova, Milan Lukas

. 2010 ; 22 (2) : 144-150.

Language English Country Great Britain Media elektronický zdroj

Document type Research Support, Non-U.S. Gov't

Grant support
NR9219 MZ0 CEP Register

BACKGROUND: The study discusses the role of antichitobioside carbohydrate antibody (ACCA), antilaminaribioside carbohydrate antibodies (ALCA), and antimannobioside carbohydrate antibodies (AMCA) in Central European patients with inflammatory bowel disease (IBD). PATIENTS AND METHODS: Twohundred and seventy-two serum samples were used - 116 Crohn's disease (CD), 84 ulcerative colitis, and 72 healthy control samples. All samples were evaluated using enzyme-linked immunosorbent assay for the following four anticarbohydrate assays: ACCA, ALCA, AMCA, and anti-Saccharomyces cerevisiae antibodies (gASCA). RESULTS: gASCA antibodies showed the highest sensitivity (67%) for a CD diagnosis, followed by AMCA (31%), ACCA (27%), and ALCA (25%). Positivity of at least one of the four assays increased the overall sensitivity of antibody testing in CD up to 85.5%. Mean serum gASCA levels were significantly higher in CD patients who were younger at diagnosis and had a longer disease duration before blood sampling (P<0.001). In nonstricturing, nonpenetrating CD, serum gASCA levels were lower than in patients with stricturing and/or penetrating behavior (P<0.05). The strongest association of gASCA was found with ileocolonic CD and with upper gastrointestinal disease (P<0.001). No association between anticarbohydrate (AMCA, ACCA, and ALCA) antibodies and CD location, behavior, age at onset, and disease duration was found; however, that sample size of some of our subgroups was probably too small to make firm conclusions on associations with all CD phenotypes. None of the assessed anticarbohydrate assays was predictive of colonic CD in patients in whom the distinction between CD and ulcerative colitis is not obvious using routine diagnostic methods. There was no relationship between the presence or concentration of anticarbohydrate antibodies and the inflammation measured by C-reactive protein levels. CONCLUSION: The use of a panel of anticarbohydrate antibodies may provide additional help in distinguishing IBD from non-IBD disease patterns. The addition of AMCA, ALCA, and ACCA assays as IBD serology markers improves the overall sensitivity of immunological examinations in IBD; however, anticarbohydrate assays are not helpful for predicting CD behavior.

Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort [elektronický zdroj] /

000      
00000naa a2200000 a 4500
001      
bmc12019261
003      
CZ-PrNML
005      
20130308083123.0
007      
ta
008      
120625s2010 xxk f 000 0eng||
009      
eAR
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Černá, Karin $7 xx0096040 $u Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic
245    10
$a Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort $h [elektronický zdroj] / $c Karin Malickova, Peter L. Lakatos, Martin Bortlik, Viktor Komarek, Ivana Janatkova, Milan Lukas
520    3_
$a BACKGROUND: The study discusses the role of antichitobioside carbohydrate antibody (ACCA), antilaminaribioside carbohydrate antibodies (ALCA), and antimannobioside carbohydrate antibodies (AMCA) in Central European patients with inflammatory bowel disease (IBD). PATIENTS AND METHODS: Twohundred and seventy-two serum samples were used - 116 Crohn's disease (CD), 84 ulcerative colitis, and 72 healthy control samples. All samples were evaluated using enzyme-linked immunosorbent assay for the following four anticarbohydrate assays: ACCA, ALCA, AMCA, and anti-Saccharomyces cerevisiae antibodies (gASCA). RESULTS: gASCA antibodies showed the highest sensitivity (67%) for a CD diagnosis, followed by AMCA (31%), ACCA (27%), and ALCA (25%). Positivity of at least one of the four assays increased the overall sensitivity of antibody testing in CD up to 85.5%. Mean serum gASCA levels were significantly higher in CD patients who were younger at diagnosis and had a longer disease duration before blood sampling (P<0.001). In nonstricturing, nonpenetrating CD, serum gASCA levels were lower than in patients with stricturing and/or penetrating behavior (P<0.05). The strongest association of gASCA was found with ileocolonic CD and with upper gastrointestinal disease (P<0.001). No association between anticarbohydrate (AMCA, ACCA, and ALCA) antibodies and CD location, behavior, age at onset, and disease duration was found; however, that sample size of some of our subgroups was probably too small to make firm conclusions on associations with all CD phenotypes. None of the assessed anticarbohydrate assays was predictive of colonic CD in patients in whom the distinction between CD and ulcerative colitis is not obvious using routine diagnostic methods. There was no relationship between the presence or concentration of anticarbohydrate antibodies and the inflammation measured by C-reactive protein levels. CONCLUSION: The use of a panel of anticarbohydrate antibodies may provide additional help in distinguishing IBD from non-IBD disease patterns. The addition of AMCA, ALCA, and ACCA assays as IBD serology markers improves the overall sensitivity of immunological examinations in IBD; however, anticarbohydrate assays are not helpful for predicting CD behavior.
650    02
$a dospělí $7 D000328
650    02
$a věk při počátku nemoci $7 D017668
650    02
$a protilátky $x krev $7 D000906
650    02
$a biologické markery $x krev $7 D015415
650    02
$a sacharidy $x imunologie $7 D002241
650    02
$a studie případů a kontrol $7 D016022
650    02
$a ulcerózní kolitida $x diagnóza $x epidemiologie $x imunologie $7 D003093
650    02
$a Crohnova nemoc $x diagnóza $x epidemiologie $x imunologie $7 D003424
650    02
$a diferenciální diagnóza $7 D003937
650    02
$a ELISA $7 D004797
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a mužské pohlaví $7 D008297
650    02
$a lidé středního věku $7 D008875
650    02
$a prediktivní hodnota testů $7 D011237
650    02
$a senzitivita a specificita $7 D012680
650    02
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lakatos, Peter L. $u First Department of Medicine, Semmelweis University, Budapest, Hungary
700    1_
$a Bortlík, Martin, $d 1970- $7 xx0058264 $u IBD Clinical and Research Centre, Charles University and ISCARE IVF, Prague, Czech Republic
700    1_
$a Komárek, Viktor $7 xx0081837 $u IBD Clinical and Research Centre, Charles University and ISCARE IVF, Prague, Czech Republic
700    1_
$a Janatková, Ivana, $7 xx0102916 $u Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic $d 1946-
700    1_
$a Lukáš, Milan, $d 1959- $7 jn19990202012 $u Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic; IBD Clinical and Research Centre, Charles University and ISCARE IVF, Prague, Czech Republic
773    0_
$t European Journal of Gastroenterology & Hepatology $g Roč. 22, č. 2 (2010), s. 144-150 $p Eur J Gastroenterol Hepatol $x 0954-691X $w MED00001618
773    0_
$p Eur J Gastroenterol Hepatol $g 22(2):144-50, 2010 Feb
910    __
$a ABA008 $y 2
990    __
$a 20120625110416 $b ABA008
991    __
$a 20130308083759 $b ABA008
999    __
$a ok $b bmc $g 913304 $s 776494
BAS    __
$a 3 $a 4
BMC    __
$a 2010 $b 22 $c 2 $d 144-150 $x MED00001618 $i 0954-691X $m European journal of gastroenterology & hepatology $n Eur J Gastroenterol Hepatol
GRA    __
$a NR9219 $p MZ0
LZP    __
$a 2012-06/lmbo

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...